Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. - Wikidata - wikimedia - TriplyDB

Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response.

Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response.

http://www.wikidata.org/entity/Q41956982

about

Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults The modulation of apoptosis by oncogenic viruses Detection of Kaposi's sarcoma associated herpesvirus nucleic acids using a smartphone accessory Clinical characteristics, predictors of immune reconstitution inflammatory syndrome and long-term prognosis in patients with Kaposi sarcoma.KS-Detect - Validation of Solar Thermal PCR for the Diagnosis of Kaposi's Sarcoma Using Pseudo-Biopsy Samples Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy.Kaposi's sarcoma: a 10-year experience with 248 patients at a single tertiary care hospital in Tanzania.Prognosis and delay of diagnosis among Kaposi's sarcoma patients in Uganda: a cross-sectional study.Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV.Update on HHV-8-Associated Malignancies Update on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.Viral profiling identifies multiple subtypes of Kaposi's sarcoma.Molecular and cellular mechanisms of KSHV oncogenesis of Kaposi's sarcoma associated with HIV/AIDS Urologic complications of HIV and AIDS.Age patterns of Kaposi's sarcoma incidence in a cohort of HIV-infected men The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro Disseminated Kaposi's Sarcoma with the Involvement of Penis in the Setting of HIV Infection Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.Extracellular Hsp90 serves as a co-factor for NF-κB activation and cellular pathogenesis induced by an oncogenic herpesvirus.Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers.A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men.A role for virally induced reactive oxygen species in Kaposi's sarcoma herpesvirus tumorigenesis.KSHV activation of VEGF secretion and invasion for endothelial cells is mediated through viral upregulation of emmprin-induced signal transduction.Kaposi's sarcoma and its associated herpesvirus.Kaposi's sarcoma-associated herpesvirus suppression of DUSP1 facilitates cellular pathogenesis following de novo infection.Multiplexed colorimetric detection of Kaposi's sarcoma associated herpesvirus and Bartonella DNA using gold and silver nanoparticles.Emmprin and KSHV: new partners in viral cancer pathogenesis.New approaches to the treatment of human herpesvirus 8-associated disease.HIV-1 Evolutionary Patterns Associated with Metastatic Kaposi's Sarcoma during AIDS.Productively infected murine Kaposi's sarcoma-like tumors define new animal models for studying and targeting KSHV oncogenesis and replication.Do we still need chemotherapy for AIDS-associated Kaposi's sarcoma?Review of latent and lytic phase biomarkers in Kaposi's sarcoma.Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy.Identifying the optimal dose of ritonavir in the treatment of malignancies.Severe Kaposi Sarcoma in an Urban Public Hospital.Intralesional bevacizumab in patients with human immunodeficiency virus-associated Kaposi's sarcoma in the upper airway.

P2860

Q24193874-CC8B7C17-EC49-41F9-88EB-A6426CC5BA59 Q26995410-FA077745-05FA-4D3D-BE67-D48EA82F2AEA Q33441496-3240AF60-8CEE-4B46-A44F-7CF7999BA352 Q33442216-67B723D0-2A47-4935-B672-7688F4F53DDE Q33446895-CFDCE9EE-A602-445B-AEF9-A47CFBAD5BD2 Q33610926-511A9828-8AFC-403E-94E2-439ACEE0352F Q33711698-6845143E-E707-453F-91F4-7FF9F465709E Q33712269-33882BF1-1E80-428A-87D8-5CE0B0F2D3F9 Q33729564-E08074C0-EE38-4360-8D68-0F830332048E Q33798426-FD01C8DF-AAFE-4B0D-9F00-F048458665FE Q33814153-2A6AF615-864E-41AA-8E25-2EAB5FF4B76C Q34168712-F8182356-500D-4B1A-88A5-C3589257D977 Q34237734-941A939F-B710-47A3-A5A3-F95CBC867C7D Q34663095-32177EEB-316C-4FD6-87E2-3D1C87D8FA05 Q34918218-0FBB5489-F1E4-4871-BA19-216FD2DE6950 Q34982616-F17247EA-FA47-4DD3-9E4A-9D60F765FC4F Q35005190-A35347D7-7B17-4AEF-AFB0-1094CECFEDB8 Q35052271-63B4528E-E90C-44BB-A623-11B6C8BE1469 Q35124404-8F52DD17-5B0B-4FFB-B81E-B16B646AE3E0 Q35208091-05390F0E-79F8-401A-B3D4-AB3369B3301F Q35298119-42F35571-F35E-450D-9A5B-803D4BA84CEC Q35827892-03EB0ABC-1AC6-446C-B8AB-B3A6FF54CD60 Q35895560-36B0E5DD-48AE-490B-AE7F-4DFFCE53C27A Q35989731-CC241FEE-0F5A-42EC-95A9-C3114C2BDA46 Q36301349-8D68E1AF-BC0A-4058-A6A7-425AFF86774E Q36415707-B5C3DCCC-A668-4C05-8129-B91BBE084DB6 Q36457808-F3904196-96F9-4C74-BA86-6DA1080A3C8C Q36487309-A8DA7CB2-B54B-4DFD-90B9-3CA8B48F1079 Q36506932-1A74B500-F16F-4B46-9933-4429629C061B Q36635800-01019BBA-4645-4C12-AACF-3A86F46F999E Q37057685-A40CD1AF-0A2E-47F5-8A9E-4EB94EAE4971 Q37211987-2C8FF518-7473-48EF-82A0-9D33707959B4 Q37250125-1A5395F0-E46E-4353-9C62-7CE53965BA09 Q37525707-4A8D7158-56F4-4FB9-A109-6FA041991075 Q38081246-7F5E4518-EF86-4626-B862-34D9003EE238 Q38144129-68E904D9-5977-45AC-BFDE-62D8B9B92C6A Q38610032-5CF1197F-DCF7-4651-8B2F-E6C7ED8FFD06 Q39061564-14E9C2D6-6DC7-484E-BC3E-7B5B20D9C2CD Q39064390-9C6554F3-E250-4EDB-8792-D2140CCF7F21 Q41688628-5B5ECC6D-6EEA-44DC-9083-0FFFA058932E

P2860

Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response.

http://www.wikidata.org/entity/Q41956982

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Persistent Kaposi sarcoma in t ...... edictors of clinical response.

@en

type

label

Persistent Kaposi sarcoma in t ...... edictors of clinical response.

@en

prefLabel

Persistent Kaposi sarcoma in t ...... edictors of clinical response.

@en

P1433

Q41956982-A6A76108-2405-4344-8031-E10A49DC7DC9

P1476

Q41956982-4AF00FE5-04FD-41A2-8E43-E734D75C9F5B

P2093

Q41956982-152A1DEE-32CB-4237-9316-DD33AE5BF41E

Q41956982-4B352C08-1718-495C-A880-59B50F19C36C

Q41956982-72FF19A6-5A4A-4494-86B1-D6D3F503219C

Q41956982-A89E3EC1-6905-4D7B-B5EE-6C7615539335

Q41956982-E485288B-6FFA-4CFB-AB29-E6C27305150E

P2860

Q41956982-0436D9AD-393B-4601-B9DF-C40AA9D38407

Q41956982-0852590B-AFC5-427E-936C-C34B181A08B4

Q41956982-09C0849C-299A-4D6B-B274-93E9EE29E4E2

Q41956982-100D6EB0-D699-49DF-8A13-DF05E43F61DF

Q41956982-11644A70-1540-4F52-B3F4-A2321C72E044

Q41956982-15811599-3756-42E3-857D-530E47B5B727

Q41956982-15B82E92-C30F-4A78-9CA2-EBF00C7B2916

Q41956982-1BA69A11-1348-41E8-8E84-B4485EB91323

Q41956982-2ADA1451-AB1F-431A-AEDE-951FBCD5E521

Q41956982-2F99A873-A39D-4D28-86E5-3AC50D9FA13F

P304

Q41956982-4310BDF4-50C5-48E6-90A5-4158CA5F77A9

P31

Q41956982-701D8885-5F42-44BF-886B-23A3357A99BF

P356

Q41956982-688F164A-30A9-4C84-AA3D-08BA699DA0BD

P407

Q41956982-169621DE-BAD1-4299-A308-15DCCCB1ECEF

P433

Q41956982-6F4E140E-5C80-4FD9-A5C9-0D629DE24A56

P478

Q41956982-58EC43F9-5CF6-4CD7-A1F0-DE48CB6EC332

P50

Q41956982-DC34DEA4-4A93-4C02-8003-D1E3F467FD90

P577

Q41956982-9D03D3BC-7EBB-4BF1-8C83-7940A875391F

P698

Q41956982-BE928CCF-04EC-49A7-8294-4546DBDF71A3

P921

Q41956982-4077A889-F0F1-4797-8093-D9DB6A927573

P932

Q41956982-A162E3F4-F17B-4985-98CB-3CD0DF7F2BA6

P356

QAD.0B013E3282FF6275

P1433

P1476

Persistent Kaposi sarcoma in t ...... edictors of clinical response.

@en

P2093

Amalia S Magaret

http://www.w3.org/2001/XMLSchema#string

Corey Casper

http://www.w3.org/2001/XMLSchema#string

Huong Q Nguyen

http://www.w3.org/2001/XMLSchema#string

Mari M Kitahata

http://www.w3.org/2001/XMLSchema#string

Stephen E Van Rompaey

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Interactions between HIV-1 Tat and KSHV.

Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.

Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.

Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997

Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy.

A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.

Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations.

Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.

Systemic treatment of AIDS-related Kaposi sarcoma: current status and perspectives.

P304

937-945

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E3282FF6275

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18453853

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

2730951

http://www.w3.org/2001/XMLSchema#string